Aanchal 
The India Vaccine Export Boost 2025 is a proud testament to the country’s global leadership in affordable and high-quality vaccine manufacturing. Post-pandemic recovery has strengthened India’s pharmaceutical exports, and vaccines are now one of the top contributors. In 2025, Indian pharma companies are seeing record-breaking success in international markets, supplying vaccines to over 150 countries. … Read more
The Pharma Pricing Policy Amendment 2025 has officially brought a new wave of price control and accessibility in India’s healthcare system. With updated price capping mechanisms and broader coverage of essential drugs, the National Pharmaceutical Pricing Authority (NPPA) has taken strong steps to regulate medicine costs in 2025. This year’s amendment ensures more transparency and … Read more
The Central Drugs Standard Control Organization (CDSCO) has officially implemented the Over-the-Counter Drug Regulation India 2025, introducing a revised framework for the sale, labeling, and promotion of non-prescription medicines. These changes aim to strengthen consumer safety, enhance product quality, and bring transparency to how OTC drugs are sold in retail and online markets across India. … Read more
The Government of India has updated the Bulk Drug Production Linked Incentive Scheme 2025, providing revised subsidies and guidelines for the manufacturing of critical Active Pharmaceutical Ingredients (APIs) within the country. This initiative supports the “Atmanirbhar Bharat” mission by reducing import dependency and boosting local pharmaceutical manufacturing. With the 2025 update, the scheme offers more … Read more
The Ministry of Health and Family Welfare has officially released the National List of Essential Medicines Update 2025, adding several new life-saving drugs to the NLEM. This update marks a significant move toward accessible and affordable healthcare in India, ensuring that vital medicines are available at regulated prices across all public and private healthcare systems. … Read more
The Indian government has officially launched the Jan Aushadhi Store Expansion Plan 2025, announcing the opening of over 5,000 new Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) across the country by March 2025. This major expansion aims to improve affordable healthcare access by increasing the availability of quality generic medicines at subsidized rates in both urban … Read more
The CDSCO Rules for New Drugs 2025 have officially come into effect, marking a major reform in India’s pharmaceutical regulatory framework. The Central Drugs Standard Control Organisation (CDSCO) has overhauled its drug approval process to reduce delays, promote innovation, and ensure faster availability of life-saving medications to the Indian population. The government has introduced automated … Read more
The Pharma Manufacturing Hubs 2025 initiative is transforming India’s pharmaceutical production landscape with state-of-the-art industrial clusters across the country. Under the Atmanirbhar Bharat and Pharma Vision 2047 programmes, the Government of India has announced the operational rollout of several new pharmaceutical manufacturing hubs aimed at boosting exports, generating employment, and strengthening drug security. These dedicated … Read more
The Indian Pharma Bulk Drug Import 2025 landscape reveals some critical trends in sourcing, cost dynamics, and dependency on global suppliers. Despite India being a global leader in generic drug manufacturing, a significant portion of Active Pharmaceutical Ingredients (APIs) and bulk drugs are still imported—especially from countries like China. In 2025, bulk drug imports have … Read more
The Government of India has officially launched the Pharma Innovation Fund India 2025, allocating ₹1500 crore to fuel pharmaceutical research and development across the country. This strategic initiative is aimed at boosting India’s self-reliance in drug discovery, biotechnology, and formulation sciences. As a part of the Department of Pharmaceuticals’ Vision 2047 roadmap, this fund is … Read more